Skip to Content
Merck
All Photos(1)

Documents

44941

Supelco

Iron(III) citrate tribasic monohydrate

18-20% Fe basis (T)

Synonym(s):

Ferric citrate monohydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C6H5FeO7 · H2O
CAS Number:
2338-05-8
Molecular Weight:
262.96
Beilstein:
4052503
EC Number:
219-045-4
MDL number:
MFCD00013098
UNSPSC Code:
12000000
PubChem Substance ID:
329756569
NACRES:
NA.21

Quality Level

100

form

solid

concentration

18-20% Fe (T)

anion traces

chloride (Cl-): ≤500 mg/kg

cation traces

Ca: ≤100 mg/kg
Cd: ≤50 mg/kg
Co: ≤50 mg/kg
Cu: ≤50 mg/kg
K: ≤500 mg/kg
Na: ≤200 mg/kg
Ni: ≤100 mg/kg
Pb: ≤50 mg/kg
Zn: ≤50 mg/kg

SMILES string

OC12CC(=O)O[Fe](OC(=O)C1)OC2=O

InChI

1S/C6H8O7.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3

InChI key

NPFOYSMITVOQOS-UHFFFAOYSA-K

Looking for similar products? Visit Product Comparison Guide

Application

Iron(III) citrate tribasic monohydrate may be used as the source of iron, in one of the compositions, used during the preparation of perfusion solutions.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H319

Hazard Classifications

Eye Irrit. 2

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCK7269
BCCH9404
BCCD4542
BCBZ5545
BCBT7358

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A E Gómez-Ayala et al.
Laboratory animals, 32(1), 72-79 (1998-03-03)
The effects of iron deficiency on the absorption of different dietary sources of iron were studied, together with the interactions between iron, calcium, phosphorus, magnesium, copper and zinc in the jejunum-ileum of control and iron-deficient rats. In this study, three
Guus A M Kortman et al.
PloS one, 7(1), e29968-e29968 (2012-01-25)
Recent trials have questioned the safety of untargeted oral iron supplementation in developing regions. Excess of luminal iron could select for enteric pathogens at the expense of beneficial commensals in the human gut microflora, thereby increasing the incidence of infectious
Keiji Nishida et al.
PLoS biology, 10(2), e1001269-e1001269 (2012-03-06)
Most organisms are simply diamagnetic, while magnetotactic bacteria and migratory animals are among organisms that exploit magnetism. Biogenic magnetization not only is of fundamental interest, but also has industrial potential. However, the key factor(s) that enable biogenic magnetization in coordination
Jamie P Dwyer et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61(5), 759-766 (2013-02-02)
Most dialysis patients require phosphate binders to control hyperphosphatemia. Ferric citrate has been tested in phase 2 trials as a phosphate binder. This trial was designed as a dose-response and efficacy trial. Prospective, phase 3, multicenter, open-label, randomized clinical trial.
Keitaro Yokoyama et al.
American journal of nephrology, 36(5), 478-487 (2012-11-14)
JTT-751 (ferric citrate hydrate) is a novel oral, iron-based phosphate binder being developed for the treatment of hyperphosphatemia among chronic kidney disease patients who are on dialysis. This study investigated the dose-response and safety of JTT-751 among Japanese hemodialysis patients.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service